The clinical significance of Epstein-Barr virus DNA in peripheral blood mononuclear cells in patients with non-Hodgkin lymphoma

References

• de-Thé G, Day NE, Geser A, et al. Sero-epidemiology of the Epstein-Barr virus: preliminary analysis of an international study-a review. IARC Sci Publ. 1975;(11 Pt 2):3–16.
   PubMedGoogle Scholar
• Niedobitek G, Agathanggelou A, Rowe M, et al. Heterogeneous expression of Epstein-Barr virus latent proteins in endemic Burkitt's lymphoma. Blood. 1995;86:659–665.
   PubMed Web of Science ®Google Scholar
• Kingma DW, Weiss WB, Jaffe ES, et al. Epstein-Barr virus latent membrane protein-1 oncogene deletions: correlations with malignancy in Epstein-Barr virus-associated lymphoproliferative disorders and malignant lymphomas. Blood. 1996;88:242–251.
   PubMed Web of Science ®Google Scholar
• Kelly G, Bell A, Rickinson A. Epstein-Barr virus-associated Burkitt lymphomagenesis selects for downregulation of the nuclear antigen EBNA2. Nat Med. 2002;8:1098–1104.
   PubMed Web of Science ®Google Scholar
• Paydas S, Ergin M, Erdogan S, et al. Prognostic significance of EBV-LMP1 and VEGF-A expressions in non-Hodgkin's lymphomas. Leuk Res. 2008;32:1424–1430.
   PubMed Web of Science ®Google Scholar
• Sun L, Zhao Y, Shi H, et al. LMP-1 induces survivin expression to inhibit cell apoptosis through the NF-κB and PI3K/Akt signaling pathways in nasal NK/T-cell lymphoma. Oncol Rep. 2015;33:2253–2260.
   PubMed Web of Science ®Google Scholar
• Kanakry J, Ambinder R. The Biology and Clinical Utility of EBV monitoring in blood. Curr Top Microbiol Immunol. 2015;391:475–499.
   PubMed Web of Science ®Google Scholar
• Jeon YK, Kim JH, Sung JY, et al. Hematopathology Study Group of the Korean Society of Pathologists. Epstein-Barr virus-positive nodal T/NK-cell lymphoma: an analysis of 15 cases with distinct clinicopathological features. Hum Pathol. 2015;46:981–990.
   PubMed Web of Science ®Google Scholar
• Jo SA, Hwang SH, Kim SY, et al. Quantitation of whole blood Epstein-Barr virus DNA is useful for assessing treatment response in patients with non-Hodgkin’s lymphoma. Int J Lab Hematol. 2010;32:e106–e113.
   PubMed Web of Science ®Google Scholar
• Park S, Lee J, Ko YH, et al. The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma. Blood. 2007;110:972–978.
   PubMed Web of Science ®Google Scholar
• Kuze T, Nakamura N, Hashimoto Y, et al. The characteristics of Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma:comparison between EBV(+) and EBV(-) cases in Japanese population. Jpn J Cancer Res. 2000;91:1233–1240.
   PubMedGoogle Scholar
• Tisi MC, Cupelli E, Santangelo R, et al. Whole blood EBV-DNA predicts outcome in diffuse large B-cell lymphoma. Leuk Lymphoma. 2016;57:628–634.
   PubMed Web of Science ®Google Scholar
• Wang ZY, Liu QF, Wang H, et al. Clinical implications of plasma Epstein-Barr virus DNA in early-stage extranodal nasal-type NK/T-cell lymphoma patients receiving primary radiotherapy. Blood. 2012;120:2003–2010.
   PubMed Web of Science ®Google Scholar
• Wang L, Wang H, Wang JH, et al. Post-treatment plasma EBV-DNA positivity predicts early relapse and poor prognosis for patients with extranodal NK/T cell lymphoma in the era of asparaginase. Oncotarget. 2015;6:30317–30326.
   PubMed Web of Science ®Google Scholar
• Ito Y, Kimura H, Maeda Y, et al. Pretreatment EBV-DNA copy number is predictive of response and toxicities to SMILE chemotherapy for extranodal NK/T-cell lymphoma, nasal type. Clin Cancer Res. 2012;18:4183–4190.
   PubMed Web of Science ®Google Scholar
• Epstein MA, Achong BG, Barr YM. Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet. 1964;1:702–703.
   PubMed Web of Science ®Google Scholar
• Molyneux EM, Rochford R, Griffin B, et al. Burkitt's lymphoma. Lancet. 2012;379:1234–1244.
   PubMed Web of Science ®Google Scholar
• Maeda E, Akahane M, Kiryu S, et al. Spectrum of Epstein-Barr virus-related diseases: a pictorial review. Jpn J Radiol. 2009;27:4–19.
   PubMed Web of Science ®Google Scholar
• Oyama T, Yamamoto K, Asano N, et al. Age-related EBV-associated B-cell lymphoproliferative disorders constitute a distinct clinicopathologic group: a study of 96 patients. Clin Cancer Res. 2007;13:5124–5132.
   PubMed Web of Science ®Google Scholar
• Lu CH, Lee KF, Chen CC, et al. Clinical characteristics and treatment outcome in a Taiwanese population of patients with Epstein-Barr virus-positive diffuse large B-cell lymphoma. Jpn J Clin Oncol. 2014;44:1164–1171.
   PubMed Web of Science ®Google Scholar
• Ok CY, Li L, Xu-Monette ZY, et al. Prevalence and clinical implications of Epstein-Barr virus infection in de novo diffuse large B-cell lymphoma in Western countries. Clin Cancer Res. 2014;20:2338–2349.
   PubMed Web of Science ®Google Scholar
• Tao Q, Ho FC, Loke SL, et al. Epstein-Barr virus is localized in the tumour cells of nasal lymphomas of NK, T or B cell type. Int J Cancer. 1995;60:315–320.
   PubMed Web of Science ®Google Scholar
• Chan KC, Zhang J, Chan AT, et al. Molecular characterization of circulating EBV DNA in the plasma of nasopharyngeal carcinoma and lymphoma patients. Cancer Res. 2003;63:2028–2032.
   PubMed Web of Science ®Google Scholar
• Lei KI, Chan LY, Chan WY, et al. Diagnostic and prognostic implications of circulating cell-free Epstein-Barr virus DNA in natural killer/T-cell lymphoma. Clin Cancer Res. 2002;8:29–34.
   PubMed Web of Science ®Google Scholar
• Kanakry JA, Hegde AM, Durand CM, et al. The clinical significance of EBV DNA in the plasma and peripheral blood mononuclear cells of patients with or without EBV diseases. Blood. 2016;127:2007–2017.
   PubMed Web of Science ®Google Scholar
• Uner A, Akyurek N, Saglam A, et al. The presence of Epstein-Barr virus (EBV) in diffuse large B-cell lymphomas (DLBCLs) in Turkey: special emphasis on EBV-positive DLBCL of the elderly. APMIS. 2011;119:309–316.
   PubMed Web of Science ®Google Scholar
• Sato A, Nakamura N, Kojima M, et al. Clinical outcome of Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly in the rituximab era. Cancer Sci. 2014;105:1170–1175.
   PubMed Web of Science ®Google Scholar
• Lu T-X, Liang J-H, Miao Y, et al. Epstein-Barr virus positive diffuse large B-cell lymphoma predict poor outcome, regardless of the age. Sci Rep. 2015;5:12168.
   PubMed Web of Science ®Google Scholar
• Kwong YL, Pang AW, Leung AY, et al. Quantification of circulating Epstein-Barr virus DNA in NK/T-cell lymphoma treated with the SMILE protocol: diagnostic and prognostic significance. Leukemia. 2014;28:865–870.
   PubMed Web of Science ®Google Scholar
• Au W-Y, Pang A, Choy C, et al. Quantification of circulating Epstein-Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patients. Blood. 2004;104:243–249.
   PubMed Web of Science ®Google Scholar
• Suzuki R, Yamaguchi M, Izutsu K, et al. Prospective measurement of Epstein-Barr virus-DNA in plasma and peripheral blood mononuclear cells of extranodal NK/T-cell lymphoma, nasal type. Blood. 2011;118:6018–6022.
   PubMed Web of Science ®Google Scholar
• Liang JH, Lu TX, Tian T, et al. Epstein-Barr virus (EBV) DNA in whole blood as a superior prognostic and monitoring factor than EBV-encoded small RNA in situ hybridization in diffuse large B-cell lymphoma. Clin Microbiol Infect. 2015;21:596–602.
   PubMed Web of Science ®Google Scholar